Becton, Dickinson and Company (BDX)

NYSE: BDX · IEX Real-Time Price · USD
+4.81 (1.97%)
Jun 29, 2022 4:00 PM EDT - Market closed
Market Cap 71.08B
Revenue (ttm) 20.03B
Net Income (ttm) 1.83B
Shares Out 285.06M
EPS (ttm) 6.35
PE Ratio 39.27
Forward PE 18.80
Dividend $3.44 (1.38%)
Ex-Dividend Date Jun 8, 2022
Volume 1,116,114
Open 244.58
Previous Close 244.53
Day's Range 243.62 - 251.17
52-Week Range 229.40 - 277.29
Beta 0.66
Analysts Buy
Price Target 289.31 (+16.0%)
Earnings Date Aug 4, 2022

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devic... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Apr 23, 1962
CEO Thomas Polen
Employees 75,000
Stock Exchange NYSE
Ticker Symbol BDX
Full Company Profile

Financial Performance

In 2021, BDX's revenue was $20.25 billion, an increase of 18.29% compared to the previous year's $17.12 billion. Earnings were $2.09 billion, an increase of 139.36%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is 289.31, which is an increase of 16.03% from the latest price.

Price Target
(16.03% upside)
Analyst Consensus: Buy
Stock Forecasts


BD (BDX) Integrates Innovative Solution to Boost Patient Care

BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.

BD's (BDX) Latest Collaboration to Enhance Patient Care

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

BD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveill...

BD is among the first companies to enter innovative partnership with Mayo Clinic Platform for access to world's largest collection of clinical data  FRANKLIN LAKES, N.J. , June 13, 2022 /PRNewswire/ -- ...

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

BD entering the new pharmacy automation solutions space via the Parata Systems acquisition

Becton, Dickson and Company (NYSE: BDX), a top medical tech corporation also known as BD, and leading private equity company, Frazier Healthcare Partners, announced they had entered into a definitive me...

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

CerTest Biotec and BD Announce Collaboration on Molecular Diagnostic Test for Monkeypox

CerTest Biotec Uses the BD MAX™ Molecular Diagnostic System Open System Reagent Suite to Develop RT-PCR Detection Kit ZARAGOZA, Spain and FRANKLIN LAKES, N.J., June 8, 2022 /PRNewswire/ -- CerTest Biote...

BD Names Simon Campion as Medical Segment President

FRANKLIN LAKES, N.J. , June 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as executi...

BD's (BDX) Latest Product to Transform Research Outcome

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.


Expands BD Transformative Solutions to Provide New Pharmacy Automation Technologies for Hospitals, Retail Pharmacy, Long-Term Care and Home Settings Advances BD 2025 Strategy to Accelerate Innovation in...

BD Unveils World's First Spectral Cell Sorter with High-Speed Imaging Technology that Sorts Cells Based on Visual Cha...

BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image Technology First to Combine Spectral Flow Cytometry with Sort-Capable Imaging FRANKLIN LAKES, N.J. , June 3, 2022 /PRNewswire/ -- BD (Becton, Dick...

BD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

FRANKLIN LAKES, N.J. , June 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs...

3 Top Dividend Kings to Buy for the Long Haul

A bear market can test investors' patience, but these companies can help you survive.

Other symbols: ABTTGT

New Strong Sell Stocks for May 27th

ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.

Other symbols: ACERBBWI

New Strong Sell Stocks for May 25th

ALGN, AUD, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2022.

Other symbols: ALGNAUD

3 Dividend Kings Trading for Bargain Prices

This suggests that ABM Industries, Becton, Dickinson & Company, and Dover could be good options for investors looking for high levels of total returns and secure income. The post 3 Dividend Kings Tradin...

Other symbols: ABMDOV

Buy These 2 Rock-Solid Stocks Instead of Exiting the Market

You'll sleep better at night, and you'll also probably get richer than if you were holding cash.

Other symbols: COST

BD (BDX) Introduces New Molecular Diagnostic Platform in US

BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.

BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection

BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.

New Strong Sell Stocks for May 13th

DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.

Other symbols: AMRNDDD

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J. , May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX)...

Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings

Expanded Collaboration Agreement to Make Less Invasive Blood Sample Collection More Convenient and Patient Centered AUSTIN, Texas and FRANKLIN LAKES, N.J. , May 11, 2022 /PRNewswire/ -- Babson Diagnosti...

7 Stock Picks to Play the Post-Pandemic Return of Dental Visits

Although Covid-19 allowed people the excuse to not see their dentist, the necessary return could benefit these dental stocks to buy. The post 7 Stock Picks to Play the Post-Pandemic Return of Dental Vis...


BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.

Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates

Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?